Assessing the role of ranibizumab in improving the outcome of glaucoma filtering surgery and neovascular glaucoma

References

• European Glaucoma Society. Terminology and guidelines for glaucoma. 4th ed. Savona: PubliComm; 2014.
   Google Scholar
• Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262–267.
   PubMed Web of Science ®Google Scholar
• Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121:2081–2090.
   PubMed Web of Science ®Google Scholar
• Garway-Heath DF, Crabb DP, Bunce C, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet. 2015;385:1295–1304.
   PubMed Web of Science ®Google Scholar
• Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268–1279.
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet. 2004;363:1711–1720.
   PubMed Web of Science ®Google Scholar
• Salim S. Current variations of glaucoma filtration surgery. Curr Opin Ophthalmol. 2012;23:89–95.
   PubMed Web of Science ®Google Scholar
• Cantor LB, Mantravadi A, WuDunn D, et al. Morphologic classification of filtering blebs after glaucoma filtration surgery: the Indiana Bleb Appearance Grading Scale. J Glaucoma. 2003;12:266–271.
   PubMed Web of Science ®Google Scholar
• Yu DY, Morgan WH, Sun X, et al. The critical role of the conjunctiva in glaucoma filtration surgery. Prog Retin Eye Res. 2009;28:303–328.
   PubMed Web of Science ®Google Scholar
• Lama PJ, Fechtner RD. Antifibrotics and wound healing in glaucoma surgery. Surv Ophthalmol. 2003;48:314–346.
   PubMed Web of Science ®Google Scholar
• Seibold LK, Sherwood MB, Kahook MY. Wound modulation after filtration surgery. Surv Ophthalmol. 2012;57(6):530–550.
   PubMed Web of Science ®Google Scholar
• Georgoulas S, Dahlmann-Noor A, Brocchini S, et al. Modulation of wound healing during and after glaucoma surgery. Prog Brain Res. 2008;173:237–254.
   PubMed Web of Science ®Google Scholar
• Holló G. Wound healing and glaucoma surgery: modulating the scarring process with conventional antimetabolites and new molecules. Dev Ophthalmol. 2017;59:80–89.
   PubMedGoogle Scholar
• Andrés-Guerrero V, Perucho-González L, García-Feijoo J, et al. Current perspectives on the use of anti-VEGF drugs as adjuvant therapy in glaucoma. Adv Ther. 2017;34:378–395.
   PubMed Web of Science ®Google Scholar
• Daneshvar R. Anti-VEGF agents and glaucoma filtering surgery. J Ophthalmic Vis Res. 2013;8:182–186.
   PubMedGoogle Scholar
• Horsley MB, Kahook MY. Anti-VEGF therapy for glaucoma. Curr Opin Ophthalmol. 2010;21:112–117.
   PubMed Web of Science ®Google Scholar
• Mathew R, Barton K. Anti-vascular endothelial growth factor therapy in glaucoma filtration surgery. Am J Ophthalmol. 2011;152:10–5.e2.
   PubMed Web of Science ®Google Scholar
• Park SC, Su D, Tello C. Anti-VEGF therapy for the treatment of glaucoma: a focus on ranibizumab and bevacizumab. Expert Opin Biol Ther. 2012;12:1641–1647.
   PubMed Web of Science ®Google Scholar
• Nissen NN, Polverini PJ, Koch AE, et al. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol. 1998;152:1445–1452.
   PubMed Web of Science ®Google Scholar
• Van Bergen T, Vandewalle E, Van de Veire S, et al. The role of different VEGF isoforms in scar formation after glaucoma filtration surgery. Exp Eye Res. 2011;93:689–699.
   PubMed Web of Science ®Google Scholar
• Lopilly Park HY, Kim JH, Ahn MD, et al. Level of vascular endothelial growth factor in Tenon tissue and results of glaucoma surgery. Arch Ophthalmol. 2012;130:685–689.
   PubMedGoogle Scholar
• Hayreh SS. Neovascular glaucoma. Prog Retin Eye Res. 2007;26:470–485.
   PubMed Web of Science ®Google Scholar
• Chen S, Zhou M, Wang W, et al. Levels of angiogenesis-related vascular endothelial growth factor family in neovascular glaucoma eyes. Acta Ophthalmol. 2015;93:e556–60.
   PubMed Web of Science ®Google Scholar
• LUCENTIS® (ranibizumab) full prescribing information leaflet. Genetech, Inc; South San Francisco, CA, USA. 2017.
   Google Scholar
• EYLEA® (aflibercept) full prescribing information leaflet. Regeneron Pharmaceuticals, Inc; Tarrytown, NY, USA. 2017.
   Google Scholar
• Palmer BF, Clegg DJ. Oxygen sensing and metabolic homeostasis. Mol Cell Endocrinol. 2014;397:51–57.
   PubMed Web of Science ®Google Scholar
• Pralhad T, Madhusudan S, Rajendrakumar K. Concept, mechanisms and therapeutics of angiogenesis in cancer and other diseases. J Pharm Pharmacol. 2003;55:1045–1053.
   PubMed Web of Science ®Google Scholar
• Bao P, Kodra A, Tomic-Canic M, et al. The role of vascular endothelial growth factor in wound healing. J Surg Res. 2009;153:347–358.
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249–257.
   PubMed Web of Science ®Google Scholar
• Rodrigues EB, Farah ME, Maia M, et al. Therapeutic monoclonal antibodies in ophthalmology. Prog Retin Eye Res. 2009;28:117–144.
   PubMed Web of Science ®Google Scholar
• Magdelaine-Beuzelin C, Pinault C, Paintaud G, et al. Therapeutic antibodies in ophthalmology: old is new again. MAbs. 2010;2:176–180.
   PubMed Web of Science ®Google Scholar
• Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005;46:726–733.
   PubMed Web of Science ®Google Scholar
• Kaiser PK. Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. Am J Ophthalmol. 2006;142:660–668.
   PubMed Web of Science ®Google Scholar
• Xu L, Lu T, Tuomi L, et al. Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach. Invest Ophthalmol Vis Sci. 2013;54:1616–1624.
   PubMed Web of Science ®Google Scholar
• Krohne TU, Liu Z, Holz FG, et al. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol. 2012;154:682–686.e682.
   PubMed Web of Science ®Google Scholar
• Kahook MY. Bleb morphology and vascularity after trabeculectomy with intravitreal ranibizumab: a pilot study. Am J Ophthalmol. 2010;150:399–403.e1.
   PubMed Web of Science ®Google Scholar
• Pro MJ, Freidl KB, Neylan CJ, et al. Ranibizumab versus mitomycin C in primary trabeculectomy — a pilot study. Curr Eye Res. 2015;40:510–515.
   PubMed Web of Science ®Google Scholar
• Lüke J, Nassar K, Lüke M, et al. Ranibizumab as adjuvant in the treatment of rubeosis iridis and neovascular glaucoma — results from a prospective interventional case series. Graefes Arch Clin Exp Ophthalmol. 2013;251:2403–2413.
   PubMed Web of Science ®Google Scholar
• Lu Q, Zou C, Cao H, et al. Preoperative intravitreal injection of ranibizumab for patients with severe proliferative diabetic retinopathy contributes to a decreased risk of postoperative neovascular glaucoma. Acta Ophthalmol. 2016;94:414–415.
   PubMed Web of Science ®Google Scholar
• Kitnarong N, Sriyakul C, Chinwattanakul S. A prospective study to evaluate intravitreous ranibizumab as adjunctive treatment for trabeculectomy in neovascular glaucoma. Ophthalmol Ther. 2015;4:33–41.
   PubMed Web of Science ®Google Scholar
• Liu L, Xu Y, Huang Z, et al. Intravitreal ranibizumab injection combined trabeculectomy versus Ahmed valve surgery in the treatment of neovascular glaucoma: assessment of efficacy and complications. BMC Ophthalmol. 2016 May 26;16:65.
   PubMed Web of Science ®Google Scholar
• Tang M, Fu Y, Wang Y, et al. Efficacy of intravitreal ranibizumab combined with Ahmed glaucoma valve implantation for the treatment of neovascular glaucoma. BMC Ophthalmol. 2016 Jan 9;16:7.
   PubMed Web of Science ®Google Scholar
• Elmekawey H, Khafagy A. Intracameral ranibizumab and subsequent mitomycin C augmented trabeculectomy in neovascular glaucoma. J Glaucoma. 2014;23:437–440.
   PubMed Web of Science ®Google Scholar
• Atchison EA, Wood KM, Mattox CG, et al. The real-world effect of intravitreous anti-vascular endothelial growth factor drugs on intraocular pressure: an analysis using the IRIS registry. Ophthalmology. 2018 Jan 11;125:676–682. pii: S0161-6420(17)31512-9. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Matušková V, Balcar VJ, Khan NA, et al. CD36 gene is associated with intraocular pressure elevation after intravitreal application of anti-VEGF agents in patients with age-related macular degeneration: implications for the safety of the therapy. Ophthalmic Genet. 2018;39:4–10.
   PubMed Web of Science ®Google Scholar
• Costagliola C, Agnifili L, Arcidiacono B, et al. Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration. Expert Opin Biol Ther. 2012;12:1299–1313.
   PubMed Web of Science ®Google Scholar
• Georgalas I, Papaconstantinou D, Tservakis I, et al. Severe hypotony and filtering bleb leak after intravitreal injection of ranibizumab. Ther Clin Risk Manag. 2009;5:17–19.
   PubMedGoogle Scholar
• Thulliez M, Angoulvant D, Le Lez ML, et al. Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis. JAMA Ophthalmol. 2014;132:1317–1326.
   PubMed Web of Science ®Google Scholar